Literature DB >> 18436796

Heparin-binding epidermal growth factor-like growth factor signaling in flow-induced arterial remodeling.

Hua Zhang1, Susan W Sunnarborg, K Kirk McNaughton, Terrance G Johns, David C Lee, James E Faber.   

Abstract

Heparin-binding epidermal growth factor (EGF)-like growth factor (HB-EGF) is activated by reduced endothelial shear stress and stimulates smooth muscle cell proliferation in vitro. Moreover, HB-EGF is augmented at sites of intimal hyperplasia and atherosclerosis, conditions favored by low/disturbed shear stress. We thus tested whether HB-EGF contributes to low flow-induced negative hypertrophic remodeling (FINR) of a mouse carotid artery. Blood flow was surgically decreased in the left and increased in the right common carotid arteries. After 21 days, the left carotid artery exhibited lumen narrowing, thickening of intima-media and adventitia, and increased circumference that were inhibited by approximately 50% in HB-EGF(+/-) and approximately 90% in HB-EGF(-/-) mice. FINR was also inhibited by the EGF receptor inhibitor AG1478. In contrast, eutrophic outward remodeling of the right carotid artery was unaffected in HB-EGF(+/-) and HB-EGF(-/-) mice, nor by AG1478. FINR-induced proliferation and leukocyte accumulation were reduced in HB-EGF(-/-). FINR was associated with increased reactive oxygen species, increased expression of pro-HB-EGF and tumor necrosis factor alpha-converting enzyme (pro-HB-EGF sheddase), increased phosphorylation of EGF receptor and extracellular signal-regulated kinase 1/2, and increased nuclear factor kappaB activity. Apocynin and deletion of p47(phox) inhibited FINR, whereas deletion of HB-EGF abolished nuclear factor kappaB activation in smooth muscle cells. These findings suggest that HB-EGF signaling is required for low flow-induced hypertrophic remodeling and may participate in vascular wall disease and remodeling.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18436796      PMCID: PMC2752633          DOI: 10.1161/CIRCRESAHA.108.171728

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  41 in total

1.  An intermediary role of proHB-EGF shedding in growth factor-induced c-Myc gene expression.

Authors:  Daisuke Nanba; Hirofumi Inoue; Yuka Shigemi; Yuji Shirakata; Koji Hashimoto; Shigeki Higashiyama
Journal:  J Cell Physiol       Date:  2008-02       Impact factor: 6.384

Review 2.  NF-kappaB activation by reactive oxygen species: fifteen years later.

Authors:  Geoffrey Gloire; Sylvie Legrand-Poels; Jacques Piette
Journal:  Biochem Pharmacol       Date:  2006-04-27       Impact factor: 5.858

3.  Reactive oxygen species mediate tumor necrosis factor alpha-converting, enzyme-dependent ectodomain shedding induced by phorbol myristate acetate.

Authors:  Z Zhang; P Oliver; J R Lancaster; P O Schwarzenberger; M S Joshi; J Cork; J K Kolls
Journal:  FASEB J       Date:  2000-12-08       Impact factor: 5.191

4.  Tumor necrosis factor-alpha converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability.

Authors:  Susan Wohler Sunnarborg; C Leann Hinkle; Mary Stevenson; William E Russell; Christina S Raska; Jacques J Peschon; Beverly J Castner; Mary J Gerhart; Raymond J Paxton; Roy A Black; David C Lee
Journal:  J Biol Chem       Date:  2002-01-31       Impact factor: 5.157

5.  Low shear stress preferentially enhances IKK activity through selective sources of ROS for persistent activation of NF-kappaB in endothelial cells.

Authors:  Sumathy Mohan; Koichi Koyoma; Amalraj Thangasamy; Hiroyasu Nakano; Randolph D Glickman; Natarajan Mohan
Journal:  Am J Physiol Cell Physiol       Date:  2006-08-16       Impact factor: 4.249

6.  Transforming growth factor-alpha mediates nuclear factor kappaB activation in strained arteries.

Authors:  Catherine A Lemarié; Pierre-Louis Tharaux; Bruno Esposito; Alain Tedgui; Stéphanie Lehoux
Journal:  Circ Res       Date:  2006-07-20       Impact factor: 17.367

7.  Flow-dependent remodeling of small arteries in mice deficient for tissue-type transglutaminase: possible compensation by macrophage-derived factor XIII.

Authors:  Erik N T P Bakker; Adrian Pistea; Jos A E Spaan; Titia Rolf; Carlie J de Vries; Nico van Rooijen; Eleonara Candi; Ed VanBavel
Journal:  Circ Res       Date:  2006-06-01       Impact factor: 17.367

8.  Localization of heparin-binding epidermal growth factor-like growth factor in human coronary arteries. Possible roles of HB-EGF in the formation of coronary atherosclerosis.

Authors:  A Nakata; J Miyagawa; S Yamashita; M Nishida; R Tamura; K Yamamori; T Nakamura; S Nozaki; K Kameda-Takemura; S Kawata; N Taniguchi; S Higashiyama; Y Matsuzawa
Journal:  Circulation       Date:  1996-12-01       Impact factor: 29.690

9.  p47phox-dependent NADPH oxidase regulates flow-induced vascular remodeling.

Authors:  Yves Castier; Ralf P Brandes; Guy Leseche; Alain Tedgui; Stéphanie Lehoux
Journal:  Circ Res       Date:  2005-08-18       Impact factor: 17.367

10.  Epidermal growth factor (EGF) activates nuclear factor-kappaB through IkappaBalpha kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IkappaBalpha.

Authors:  G Sethi; K S Ahn; M M Chaturvedi; B B Aggarwal
Journal:  Oncogene       Date:  2007-05-28       Impact factor: 9.867

View more
  14 in total

1.  Early immune responses are independent of RGC dysfunction in glaucoma with complement component C3 being protective.

Authors:  Jeffrey M Harder; Catherine E Braine; Pete A Williams; Xianjun Zhu; Katharine H MacNicoll; Gregory L Sousa; Rebecca A Buchanan; Richard S Smith; Richard T Libby; Gareth R Howell; Simon W M John
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-26       Impact factor: 11.205

2.  Heparin-binding EGF-like growth factor (HB-EGF) antisense oligonucleotide protected against hyperlipidemia-associated atherosclerosis.

Authors:  S Kim; M J Graham; R G Lee; L Yang; S Kim; V Subramanian; J D Layne; L Cai; R E Temel; D Shih; A J Lusis; J A Berliner; S Lee
Journal:  Nutr Metab Cardiovasc Dis       Date:  2019-01-09       Impact factor: 4.222

3.  Can we fight chronic kidney disease by targeting endothelial HB-EGF?

Authors:  Analia S Loria
Journal:  Am J Physiol Renal Physiol       Date:  2016-06-22

4.  A disintegrin and metalloprotease 17 mediates neointimal hyperplasia in vasculature.

Authors:  Akira Takaguri; Keita Kimura; Akinari Hinoki; Allison M Bourne; Michael V Autieri; Satoru Eguchi
Journal:  Hypertension       Date:  2011-02-28       Impact factor: 10.190

5.  Increased epidermal growth factor-like ligands are associated with elevated vascular nicotinamide adenine dinucleotide phosphate oxidase in a primate model of atherosclerosis.

Authors:  Bojana Stanic; Deepesh Pandey; David J Fulton; Francis J Miller
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-08-09       Impact factor: 8.311

Review 6.  Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives.

Authors:  Jeng-Jiann Chiu; Shu Chien
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

7.  Impact of brief exercise on circulating monocyte gene and microRNA expression: implications for atherosclerotic vascular disease.

Authors:  Shlomit Radom-Aizik; Frank P Zaldivar; Fadia Haddad; Dan M Cooper
Journal:  Brain Behav Immun       Date:  2014-01-11       Impact factor: 7.217

8.  The expression of heparin-binding epidermal growth factor-like growth factor by regulatory macrophages.

Authors:  Justin P Edwards; Xia Zhang; David M Mosser
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

9.  Epidermal Growth Factor Receptor Transactivation: Mechanisms, Pathophysiology, and Potential Therapies in the Cardiovascular System.

Authors:  Steven J Forrester; Tatsuo Kawai; Shannon O'Brien; Walter Thomas; Raymond C Harris; Satoru Eguchi
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-11-09       Impact factor: 13.820

Review 10.  Hemodynamic shear stress and the endothelium in cardiovascular pathophysiology.

Authors:  Peter F Davies
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.